Evopoint Biosciences

Executive Summary

Evopoint Biosciences is a private, innovation-driven biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing transformative therapies for precision oncology and multidrug-resistant infections. Founded in 2020, the company leverages three core technology platforms to create best-in-class biologics, antibodies, and small molecules. Despite its pre-clinical designation, Evopoint claims multiple assets in late-stage clinical trials, suggesting a mature pipeline. The company's strategic emphasis on high-unmet-need areas positions it for potential value creation, though limited public information constrains detailed assessment. Evopoint's private status and lack of disclosed funding or valuation data add uncertainty, but its science-driven approach and focus on resistant infections and oncology align with current market trends.

Upcoming Catalysts (preview)

• Q3 2026Phase 2/3 Clinical Data Readout for Lead Oncology Asset60% success
• Q4 2026Series B or C Financing Round70% success
• H2 2026Strategic Partnership or Licensing Deal for Antibiotic Platform50% success